In uremia, plasma levels of anti-protein C and anti-protein S antibodies are associated with thrombosis

Kidney International

Volumn 68, Issue 3, 2005, Pages 1223-1229

  Molino, Daniela ^b   De Lucia, Domenico ^b   Marotta, Rosa ^b   Perna, Alessandra ^b   Lombardi, Cinzia ^b   Cirillo, Massimo ^b   De Santo, Natale Gaspare ^a  

^a SECOND UNIVERSITY OF NAPLES   (Italy)

^b NONE

Author keywords

Anti protein C antibody; Dialysis; Endothelial damage; Hemostasis; Thrombosis

Indexed keywords

ACTIVATED PROTEIN C; ANTITHROMBIN III; BETA2 GLYCOPROTEIN 1; BLOOD CLOTTING FACTOR; BLOOD CLOTTING FACTOR 10; BLOOD CLOTTING FACTOR 7; BLOOD CLOTTING FACTOR 8; C REACTIVE PROTEIN; CARDIOLIPIN ANTIBODY; D DIMER; FIBRINOGEN; FIBRINOLYTIC FACTOR; HOMOCYSTEINE; PHOSPHOLIPID ANTIBODY; PLASMINOGEN; PLASMINOGEN ACTIVATOR INHIBITOR 1; PROTEIN ANTIBODY; PROTEIN C; PROTEIN C ANTIBODY; PROTEIN S; PROTEIN S ANTIBODY; PROTHROMBIN; PROTHROMBIN ANTIBODY; TISSUE PLASMINOGEN ACTIVATOR; UNCLASSIFIED DRUG;

ADULT; ARTICLE; CONTROLLED STUDY; ENDOTHELIUM LESION; FEMALE; HEMODIALYSIS; HUMAN; MAINTENANCE THERAPY; MAJOR CLINICAL STUDY; MALE; MEDICAL LITERATURE; PRIORITY JOURNAL; PROTEIN BLOOD LEVEL; PROTHROMBIN TIME; THROMBOSIS; UREMIA;

ANTIBODIES, ANTIPHOSPHOLIPID; ENDOTHELIUM, VASCULAR; FEMALE; HEMOSTASIS; HUMANS; MALE; MIDDLE AGED; PROTEIN C; PROTEIN S; SEROEPIDEMIOLOGIC STUDIES; THROMBOSIS; UREMIA;

EID: 29244461364     PISSN: 00852538     EISSN: 15231755     Source Type: Journal    
DOI: 10.1111/j.1523-1755.2005.00515.x     Document Type: Article

References (33)

1. VAZIRI ND, GONZALES EC, WANG J, et al: Blood coagulation, fibrinolytic, and inhibitory proteins in end-stage renal disease: Effect of hemodialysis. Am J Kidney Dis 23:828-835, 1994
2. RABELIN KTJ, ZWAGINGER JJ, KROMANS HA, et al: Thrombosis and haemostasis in renal disease. Kidney Int 46:287-296, 1994
3. FELDMAN HI, HELD PJ, HUTCHINSON JT, et al: Haemodialysis vascular access morbidity in the United States. Kidney Int 43:1091-1096, 1993
4. VAZIRI ND, TOOHEY J, PAULE P, et al: Coagulation abnormalities in patients with end-stage renal disease treated with hemodialysis. Int J Artif Organs 7:323-326, 1984
5. VANHERWEGHEM JL, YASSINE T, GOLDMANN M, et al: Subclavian vein thrombosis: A frequent complication of subclavian vein cannulation for hemodialysis. Clin Nephrol 26:235-238, 1986
6. OPATRNY K, JR., MARES J, VIT L, et al: Fibrinolysis and metabolic disturbances in hemodialysis patients. Nieren- und Hochdruckkrankheiten 11:505-515, 2001
7. OPATRNY K, JR., ZEMANOVÀ P, MARES J, et al: Fibrinolysis defect in long term hemodialysis patients with type 2 diabetes mellitus and its relation to metabolic disorders. Am J Nephrol 22:429-436, 2002
8. DE MARCHI S, FALLETI E, GIACOMELLO R, et al: Risk factors for vascular disease and arteriovenous fistula dysfunction in hemodialysis patients. J Am Soc Nephrol 7:1169-1177, 1996
9. SEGARRA A, CHACON P, MARTINEZ-EYARRE C, et al: Circulating levels of plasminogen activator inhibitor type-1, tissue plasminogen activator, and thrombomodulin in hemodialysis patients: Biochemical correlations and role as independent predictors of coronary artery stenosis. J Am Soc Nephrol 12:1255-1263, 2001
10. VAZIRI ND, TOOHEY J, PAULE P, et al: Coagulation abnormalities in patients with end-stage renal disease treated with hemodialysis. Int J Artif Organs 7:323-326, 1984
11. ISHII Y, YANO S, KANAI H, et al: Evaluation of blood coagulation- fibrinolysis system in patients receiving chronic hemodialysis. Nephron 73:407-412, 1996
12. BASKIN E, DUMAN O, BESBAS N, et al: Hypercoagulopathy in a hemodialysis patient: Are elevations in Factors VII and VIII effective? Nephron 83:180, 1999
13. LAI K, YIN JA, YUEN PMP, et al: Effect of hemodialysis on protein C, protein S and antithrombin II levels. Am J Kidney Dis 17:38-42, 1991
14. PALOMO I, PEREIRA J, ALARCON M, et al: Vascular access thrombosis is not related to presence of antiphospholipid antibodies in patients on chronic hemodialysis. Nephron 92:957-958, 2002
15. DUCLOUX D, FLOREA A, REBIBOU JM, et al: Anti-beta2-glycoprotein I and anti-prothrombin antibodies in haemodialysis patients. Nephrol Dial Transplant 12:2466, 1997
16. ADLER S, SZCZECH L, QURESHI A, et al: IgM anticardiolipin antibodies are associated with stenosis of vascular access in hemodialysis patients but do not predict thrombosis. Clin Nephrol 56:428-434, 2001
17. ASHERSON RA, HARRIS EN: Anticardiolipin antibodies-clinical associations. Postgrad Med J 62:1081-1087, 1986
18. MANNS BJ, BURGESS ED, PARSONS HG, et al: Hyperhomocysteinemia, anticardiolipin antibody status, and risk for vascular access thrombosis in hemodialysis patients. Kidney Int 55:315-320, 1999
19. PRAKASH R, MILLER CC 3RD, SUKI WN: Anticardiolipin antibody in patients on maintenance hemodialysis and its association with recurrent arteriovenous graft thrombosis. Am J Kidney Dis 26:347-352, 1995
20. MOLINO D, DE SANTO NG, MAROTTA R, et al: Plasma levels of plasminogen activator inhibitor type 1, Factor VIII, prothrombin activation fragment 1+2, anticardiolipin, and antiprothrombin antibodies are risk factors for thrombosis in hemodialysis patients. Semin Nephrol 24:495-501, 2004
21. CHEW SL, LINS RL, DAELEMANS R, et al: Are antiphospholipid antibodies clinically relevant in dialysis patients? Nephrol Dial Transplant 14:1194-1198, 1992
22. ANGLES-CANO E, GUILLIN MC: Antiphospholipid antibodies and the coagulation cascade. Clin Chem 47:1008-1015, 2001
23. PERNA AF, INGROSSO D, DE SANTO NG, et al: Mechanism of erythrocyte accumulation of methylation inhibitor S-adenosylHomocysteine in uremia. Kidney Int 47:247-253, 1995
24. NOJIMA J, KURATSUNE H, SUEHISA E, et al: Acquired activated protein C resistance associated with anti-protein S antibody as a strong risk Factor for DVT in non-SLE patients. Thromb Haemost 88:716-722, 2002
25. NOJIMA J, KURATSUNE H, SUEHISA E, et al: Association between the prevalence of antibodies to beta(2)-glycoprotein I, prothrombin, protein C, protein S, and annexin V in patients with systemic lupus erythematosus and thrombotic and thrombocytopenic complications. Clin Chem 47:1008-1015, 2001
26. NOJIMA J: Association between anti-phospholipid antibodies and thrombotic complications in systemic lupus erythematosus. Rinsho Byori 51:239-247, 2003
27. PENGO V, BIASIOLO A, BROCCO T, et al: Autoantibodies to phospholipid-binding plasma proteins in patients with thrombosis and phospholipid-reactive antibodies. Thromb Haemost 75:721-724, 1996
28. SPITTLE MA, HOENICH NA, HANDELMAN GJ, et al: Oxidative stress and inflammation in hemodialysis patients. Am J Kidney Dis 38:1408-1413, 2001
29. BORAWSKI J, NAUMNIK B, PAWLAK K, et al: Endothelial dysfunction marker von Willebrand Factor antigen in haemodialysis patients: Associations with pre-dialysis blood pressure and the acute phase response. Nephrol Dial Transplant 16:1442-1447, 2001
30. ATSUMI T, KHAMASHTA A, AMENGUAL O, et al: Binding of anticardiolipin antibodies to protein C via beta2-glycoprotein I (beta2-GPI): A possible mechanism in the inhibitory effect of antiphospholipid antibodies on the protein C system. Clin Exp Immunol 112:325-333, 1998
31. KOUKE-MARCHANT K: Genetic polymorphisms associated with venous and arterial thrombosis. Arch Pathol Lab Med 126:295-304, 2002
32. PERNA AF, INGROSSO D, DE SANTO NG: Homocysteine and oxidative stress. Amino Acids 25:409-417, 2003
33. PERNA AF, INGROSSO D, LOMBARDI C, et al: Possible mechanisms of homocysteine toxicity. Kidney Int 84:137-140, 2003